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FIRST, DO NO HARM
The risks of overtreating children with epilepsy 
Eunice Chuang1, Marilisa M. Guerreiro4, Sara Y. Tsuchie1, 
Angelica Santucci2, Carlos A. M. Guerreiro4, Maria Augusta Montenegro3
ABSTRACT - Background: Although overtreatment with antiepileptic drugs contributes to the morbidity
associated with epilepsy, many children still are overtreated. Objective: To evaluate if the withdrawal of
at least one antiepileptic drug (AED) in children with refractory epilepsy using polytherapy enable a bet-
ter seizure control. Method: This was a prospective study. Children with refractory epilepsy using at least
two AEDs were included. Once the patient, or guardian, agreed to participate in the study, one or more
AED were slowly tapered off. The remaining AEDs dosages could be adjusted as needed, but a new AED
could not be introduced. Results: Fifteen patients were evaluated, three girls; ages ranging from 3 to 18
(mean=8.7 years). After at least one AED withdrawal, two (13.5%) patients became seizure free, seizures
improved >50% in 5 (33.5%) patients, did not change in 5 (33.5%), and seizure frequency became worse
in 3 (20%). Adverse events improved in 12 patients (80%). Conclusion: The withdrawal of at least one
AED is a valuable option in the treatment of selected children with refractory epilepsy.
KEY WORDS: epilepsy, children, antiepileptic drug, overtreatment.
Primeiramente, não causar dano: os riscos do excesso de medicações no tratamento da epilep-
sia na infância
RESUMO - Introdução: Apesar do tratamento excessivo com drogas antiepilépticas (DAE) contribuir para
a morbidade associada à epilepsia, muitas crianças ainda são submetidas a politerapia desnecessária.
Objetivo: Avaliar se a retirada de pelo menos uma DAE em crianças com epilepsia refratária utilizando
politerapia pode proporcionar melhor controle das crises epilépticas. Métodos: Este foi um estudo prospec-
tivo. Crianças com epilepsia refratária em uso de pelo menos duas DAE foram incluídas. Após assinatura
do consentimento informado, uma ou mais DAE foram lentamente retiradas. As doses das outras DAE que
não foram retiradas poderiam ser ajustadas se necessário, mas uma nova DAE não pode ser introduzida.
Resultados: Quinze pacientes foram avaliados, três eram meninas, com idades entre 3 e 18 anos (média=8,7).
Após a retirada de pelo menos uma DAE, 2 (13,5%) pacientes ficaram livre de crises, as crises melhoraram
em 5 (33,5%), não mudaram em 5 (33,5%) e a frequencia das crises pioraram em 3 (20%) pacientes. Os
eventos adversos melhoraram em 12 patientes (80%). Conclusão: A retirada de pelo menos uma DAE é
uma opção válida no tratamento de crianças com epilepsia refratária. 
PALAVRAS-CHAVE: epilepsia, infância, droga antiepiléptica, tratamento excessivo.
Most children with epilepsy become seizure free
after the introduction of one antiepileptic drug
(AED)1,2. There is universal agreement that the pre-
scription of a single agent at the lowest therapeutic
dosage constitutes the best practice in the treatment
of epilepsy3,4. This is the only way to avoid the risks
of AED overtreatment4. Despite that, the use of poly-
therapy remains, especially if the first AED fails to
control the seizures.
It is known that the reduction of one or more AED
is possible without an increase in seizure frequency5-7.
Moreover, AEDs may aggravate pre-existing seizures
and trigger new seizure types8. 
The objective of this study was to evaluate if the
withdrawal of at least one AED in children with re-
fractory epilepsy using polytherapy can improve sei-
zure control. 
METHOD
This was a prospective study conducted at the pediatric
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epilepsy clinic of our University Hospital from January 2005
to December 2005. Inclusion criteria consisted of age
between 1 and 18 years-old, diagnosis of refractory epilep-
sy, use of at least two AEDs, signature of informed consent
approved by the Ethical Committee of our institution. 
Once the patient, or guardian, agreed to participate in
the study, one or more AEDs were slowly tapered off. The
remaining AEDs dosages could be adjusted as needed, but
a new AED could not be introduced.
After drug withdrawn we assessed seizure frequency
and adverse events. Routine visits were scheduled and
patients were instructed to seek medical care at our insti-
tution as needed, especially in case of seizure exacerbation. 
RESULTS
Fifteen patients met the inclusion criteria and
were included in the protocol, three girls and 10 boys;
ages ranging from 3 to 18 (mean=8.7 years). Table 1
shows the characteristics of the patients.
After at least one AED withdrawal, two (13.5%)
patients became seizure free, seizures improved
>50% in 5 (33.5%) patients, did not change in 5
(33.5%), and seizure frequency became worse in 3
(20%). Adverse events improved in 12 patients (80%;
Table 2).
It should be noted that due to ethical issues, the
doses of the remaining AED could be adjusted as
needed. This probably contributed to seizure impro-
vement in two patients (patients 2 and 8). However,
five patients (patients 9, 10, 12, 13 and 14) present-
ed improvement in seizure control after the with-
draw of one AED, without any modification in the
remaining AEDs dosages.
DISCUSSION
There is no question that seizure freedom is the
main goal for patients, families and doctors dealing
with epilepsy. However, a small percentage of children
Table 1. Characteristics of the patients.
ID Gender/Age Etiology of epilepsy Neuroimaging Type of epileptic syndrome Neurological examination
1 5/F Chiari II malformation Hydrocephalus Partial Developmental delay, 
macrocephaly, lower limb
hypotonia and paresis
2 12/M Criptogenic Normal Partial Normal
3 3/F Criptogenic Normal Indeterminated Developmental delay
4 15/M Neonatal complications
(mainly hypoglicemia)
Gliosis Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
tetraparesis
5 6/M Brain malformation Bilateral
schizencefaly
Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
tetraparesis, subnormal vision
6 13/M Perinatal complications Periventricular
leucomalacia
Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
tetraparesis
7 3/M Neonatal complication
(mainly prematurity)
Hydrocefalus Generalized (West 
syndrome)
Developmental delay, 
tetraparesys
8 12/M Unkown Normal Partial Developmental delay, 
mental retardation
9 5/M Hypoxic ischemic
Encephalopathy
Focal atrophy Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
hypotonia 
10 12/M Unknown Normal Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
mental retardation
11 18/M Unknown Normal Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
mental retardation
12 6/M Meningoencephalitis Multicystic 
leucomalacia
Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
tetraparesis and microcephaly
13 8/M Myoclonic astatic 
epilepsy
Normal Generalized Developmental delay, 
mental retardation
14 10/M Criptogenic Normal Generalized (Lennox-
Gastaut syndrome)
Developmental delay, 
mental retardation
15 4/F Meningoencephalitis Normal Generalized (Lennox-
Gastaut syndrome)
Developmental delay, mental
retardation, global hypotonia
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Table 2. Adverse events and seizure control after AED withdrawal.
ID AED Adverse 
event
Number of
seizures at
baseline
AED 
withdrawn
Adverse event
after AED 
withdrawal
Seizures after
AED with-
drawal
Follow-
up
1 DPH (6.5 mg/kg/d)
PB (3.6 mg/kg/d) 
Apathy 4 / day PB Improved Worse -
2 CBZ (15 mg/kg/d)
DPH (5 mg/kg/d)
CLB (5 mg/d)
None 20 / day CLB DPH 
↑ CBZ (22,5 mg/kg/d)
No 
improvement
Improved
(seizure-free)
12
months
3 LTG (6 mg/kg/d)
VA (25 mg/kg/d)
CLB (20 mg/d)
None 1 / week VA 
CLB  
↑ LTG (200 mg)
Improved No 
improvement
10
months
4 VA (29 mg/kg/d)
LTG (8,8 kg/d)
TPM (5,8 mg/kg/d) 
CZP (0,5 mg/kg/d) 
NTZ (5 mg/kg/d)
Somnolence 2-3 / day CZP
NTZ
Improved No 
improvement
6
months
5 CLB (10 ml/d) 
LTG (200 mg/d) 
VGB (1000 mg/d)
None 20 / day VGB No 
improvement
Worse -
6 NTZ (15 mg/d) 
CBZ (1000 mg/d) 
PB (100 mg/d)
Somnolence,
apathy, 
poor school 
attendance/ 
performance
3-10 / day PB Improved No 
improvement
12
months
7 VA (40 mg/kg/d) 
CLB (2 mg/kg/day) 
VGB (100 mg/kg/day)
Somnolence,
apathy
Daily 
seizures
VGB
↑ VA (50 mg/kg/day) 
↑ CLB (2.2mg/kg/d)
Improved No 
improvement
8
months
8 VA (18 mg/kg/day) 
FB (5 mg/kg/day) 
CZP (0.5 mg/day)
Somnolence,
apathy
15 / day PB
CZP
↑ VA (25 mg/kg/day)
Improved Improved
(seizure-free) 
12
months
9 FB (3 mg/kg/day) 
VA (56 mg/kg/day) 
CLB (40 mg/day)
Somnolence,
apathy
5 / day PB Improved Improved: 0-2
seizures / day 
6
months
10 LTG (350 mg/day) 
CLB (45 mg/day) 
TPM (150 mg/day)
Somnolence,
apathy
4 / day TPM Improved Improved
80%
12
months
11 CZP (3.5 mg/day) 
CBZ (900 mg/day) 
VA (250 mg/day)
None 9 / week VA No 
improvement
Worse -
12 DPH (7 mg/kg/day) 
PB (3.6 mg/kg/day)
Somnolence,
apathy, gun
hypertrophy, 
hypertricosis
30 / day DPH Improved Improved: 0-3
seizures/day
2 month
13 LTG (400 mg/day) 
CZP (3 mg/day)
Somnolence,
apathy
2 / week LTG Improved Improved:
1/month
3 month
14 TPM (3 mg/kg/day) 
CLB (20 mg/day) 
VA (39 mg/kg/day)
Somnolence,
apathy, lost of
weight
15 / day TPM Improved Improved: 5
seizures / day
1 month
15 PB (5 mg/kg/dia) 
VA (30 mg/dkg/day) 
CZP (1 mg/day)
Somnolence,
apathy
4 / day PB Improved No 
improvement
3
months
AED, antiepileptic drug; CBZ, carbamazepine; CLB, clobazam; CZP, clonazepam; DPH, phenytoin; PB, phenobarbital; TPM, topiramate; VA, valproate;
LTG, lamotrigina; NTZ, nitrazepam; VGB, vigabatrin.
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will present refractory seizures, and will not become
seizure-free despite adequate AED treatment9-11.
Epilepsy generally demands prolonged AED treatment
which is often associated with drug toxicity, especial-
ly when there is the use of an excessive – and some-
times unnecessary – number of AEDs4,12-14.
Although there is increasing awareness that over-
treatment with AEDs contributes to the morbidity
associated with epilepsy4, many children still are over-
treated. One possible explanation can be the fact
that seizures are probably one of the most frighten-
ing event a parent can experience. For that reason,
parents often will take the child with refractory
epilepsy to as many doctors as needed to have their
seizures controlled. In addition, most parents will try
almost anything if there is a small hope of seizure
freedom. As for doctors, it is sometimes too hard to
resist the family’s desperate question “Can we add
a new drug?”
Our findings show that the reduction of one or
more AED is possible without an increase in seizure
frequency, which is in keeping with other studies5-7.
In addition, two patients became seizure free.
It should be kept in mind that the outcome of
epilepsy treatment should not be measured only by
the percentage of seizure reduction15. Quality of life
is related not only to seizure control, but also to ad-
verse events. We found that the withdraw of one
AED provided a considerable improvement in the
adverse events of five (33.5%) patients despite of no
improvement in seizure control. This enable a better
quality of life, and families referred that their chil-
dren were feeling much better, despite no seizure
control.
Epilepsy is a frightening condition, and some fam-
ilies cannot cope with a single febrile seizure. How-
ever, it is surprising how well many parents of a se-
verely handicapped child – and above all, the chil-
dren themselves – can sometimes cope very well with
seizures. After the protocol, the substantial improve-
ment in drug related adverse events enabled one of
our patients with cerebral palsy to go back to school
(patient 6). 
One possible limitation of our study was that,
according to ethical issues, the remaining AEDs
dosages could be adjusted as needed. Higher doses
of the remaining AED probably contributed to seizure
improvement in two patients. However, five patients
presented improvement in seizure control after the
withdraw of one AED, without any modification in
the remaining AEDs dosages.
We conclude that although a larger sample is
needed in order to confirm our findings, the reduc-
tion of one AED in selected children with refractory
epilepsy can be associated with less adverse events
and better quality of life without worsening of sei-
zure frequency. In addition, a few patients may pres-
ent an improvement in seizure control.
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